Recent Updates
Recently added Catalysts

Kineret

Phase 1

Familial Cold Urticaria | Small molecule | Immunology |Atlantic International Corp.|Last Updated: Nov 8, 2022

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLEDBiomarker
Total Trials1
Total Enrollment8

FDA Designations

No designations recorded

Clinical trial landscape

Kineret · 1 trial · 1 indication

Phase 1 1
NCT00214851The Use of Kineret (Anakinra) in the Treatment of Familial Cold UrticariaFamilial Cold Urticaria
COMPLETED8 Analytics
PHASE1COMPLETED
The Use of Kineret (Anakinra) in the Treatment of Familial Cold Urticaria
Familial Cold Urticaria
NCT002148518
Unlock trial analytics

Study Endpoints

Primary Endpoints

To determine the efficacy of kineret (anakinra) 100mg./day in subjects with familial cold urticaria.
Eight weeks

Secondary Endpoints

To demonstrate the use of C-Reactive Protein (CRP) and Serum Amyloid A Protein (SAA) levels as objective laboratory indicators of effective treatment and to compare the results of two different laboratory methods for the estimation of CRP
Eight weeks
Unlock Study Endpoints

Study Design & Arms

AllocationNON_RANDOMIZED
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Interventions

NameTypeDescription
Kineret (anakinra)DRUGKineret (anakinra 100 mg. s/c daily x 4 weeks
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * Must be 18 years of age or older at the time of enrollment; may be male or female * Must be previously diagnosed with Familial Cold Urticaria (FCU) * Must react with at least one of the symptoms of FCU in the summer months at least four times per week sufficiently to interfere...

Countries:Canada
Unlock Eligibility Criteria

Frequently asked questions about Kineret

What is Kineret used for in Familial Cold Urticaria?

Kineret is used for the treatment of Familial Cold Urticaria, a condition in which exposure to cold triggers symptoms. It is being developed by Atlantic International Corp. and is currently in Phase 1 clinical development as an investigational therapy for this indication.

What does Kineret target?

Kineret is a small molecule being studied for its effects in Familial Cold Urticaria. The specific molecular target has not been disclosed in the available information, so its mechanism of action in this condition is not detailed here.

Who makes Kineret?

Kineret is being developed by Atlantic International Corp., which trades under the ticker ATLN. The company is conducting clinical research on this drug for the treatment of Familial Cold Urticaria.

What phase is Kineret in?

Kineret is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 trial has been completed, and the drug remains under study for Familial Cold Urticaria.

What clinical trials is Kineret in?

Kineret has been studied in one clinical trial, NCT00214851, titled 'The Use of Kineret (Anakinra) in the Treatment of Familial Cold Urticaria.' This Phase 1 study was completed in Canada and enrolled 8 participants aged 18 years and older.

Is Kineret the same as Anakinra?

Kineret is also known as Anakinra. The clinical trial NCT00214851 refers to Kineret as Anakinra, indicating that these names are used interchangeably for the same drug in the context of this study.